U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07890376) titled 'A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes' on Oct. 16.
Brief Summary: The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who have overweight with a weight-related health condition.
Participation in the study will last about 58 weeks.
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
Obesity
Overweight
Intervention:
DRUG: LY4086940
Administered oral...